Acute myeloid leukemia after myeloproliferative neoplasms: Real‐world outcomes in the new treatment era in the United States
Cancer · 2026
DOI: 10.1002/cncr.70415 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2026. Verfasst von Jan Philipp Bewersdorf und 8 weiteren Autor:innen. Beteiligte Einrichtung: Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Myeloproliferative Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Flatiron Health.
Abstract (Originalsprache)
Background
Progression to acute myeloid leukemia (AML) is a rare complication of myeloproliferative neoplasms (MPNs) with limited treatment options and median overall survival (OS) of 3–6 months. The treatment of AML has been revolutionized in recent years with the introduction of novel targeted therapies including the BCL2 inhibitor venetoclax (VEN). However, evidence regarding outcomes in patients with post‐MPN AML remains limited.
Methods
To evaluate the impact of novel therapies on the outcomes of patients with post‐MPN AML, the authors conducted a retrospective analysis of 392 patients who were diagnosed with post‐MPN AML during 2014–2024 in the United States and were included in the Flatiron Health Research Database.
Results
Although the proportion of patients treated with lower‐intensity therapies (LIT) including VEN in combination with hypomethylating agents increased over time, OS was very similar among patients diagnosed before and after VEN approval (median OS, 7.1 [95% confidence interval (CI), 5.7–9.5] months vs. 7.6 [95% CI, 5.8–10.1] months; p = .39). Only 15% of post‐MPN AML patients underwent an allogeneic hematopoietic cell transplant (allo‐HCT). Those who received allo‐HCT experienced better OS than patients who did not receive allo‐HCT (median OS, 20.5 [95% CI, 15.4–36.2] months vs. 5.8 [95% CI, 5.0–6.8] months; p < .01). Although patients treated with intensive chemotherapy (IC) had longer OS than those treated with LIT (hazard ratio, 1.95; 95% CI, 1.12–3.41; p = .02), patients receiving IC and LIT as a bridge to allo‐HCT had comparable OS ( p = .37).
Conclusions
This study highlights allo‐HCT as the only potentially curative option with both IC and LIT serving as effective bridging therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
- Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA.
- Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA.
- Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale School of Medicine, New Haven, Connecticut, USA.
ORCID-Profile: Jan Philipp Bewersdorf, Rong Wang, Amer M Zeidan, Nikolai A Podoltsev
Förderung
- Flatiron Health
Zitieren
APA
Bewersdorf, J. P., Wang, R., Mendez, L., Mina, A., Aguirre, L. E., Stahl, M., Zeidan, A. M., Ma, X., & Podoltsev, N. A. (2026). Acute myeloid leukemia after myeloproliferative neoplasms: Real‐world outcomes in the new treatment era in the United States. Cancer. https://doi.org/10.1002/cncr.70415
Vancouver
Bewersdorf JP, Wang R, Mendez L, Mina A, Aguirre LE, Stahl M, et al. Acute myeloid leukemia after myeloproliferative neoplasms: Real‐world outcomes in the new treatment era in the United States. Cancer. 2026. doi:10.1002/cncr.70415
BibTeX
@article{Bewersdorf2026,
author = {Bewersdorf, Jan Philipp and Wang, Rong and Mendez, Lourdes and Mina, Alain and Aguirre, Luis E and Stahl, Maximilian and Zeidan, Amer M and Ma, Xiaomei and Podoltsev, Nikolai A},
title = {Acute myeloid leukemia after myeloproliferative neoplasms: Real‐world outcomes in the new treatment era in the United States},
journal = {Cancer},
year = {2026},
doi = {10.1002/cncr.70415}
}
EUVIMED